These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 14530617)

  • 1. Primary and secondary stroke prevention in nonrheumatic atrial fibrillation by oral anticoagulation.
    Stöllberger C; Finsterer J
    Eur Neurol; 2003; 50(3):127-35. PubMed ID: 14530617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
    Potpara TS; Lip GY
    Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
    Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
    Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.
    Lip GY
    Am J Med; 2011 Feb; 124(2):111-4. PubMed ID: 20887966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.
    European Atrial Fibrillation Trial Study Group
    N Engl J Med; 1995 Jul; 333(1):5-10. PubMed ID: 7776995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral anticoagulation in chronic kidney disease with atrial fibrillation].
    Expósito V; Seras M; Fernández-Fresnedo G
    Med Clin (Barc); 2015 May; 144(10):452-6. PubMed ID: 24889748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland.
    Bednarski J; Cieszewska E; Strzelecki A; Filipiak KJ
    Kardiol Pol; 2013; 71(12):1260-5. PubMed ID: 23990227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electronic Alert System for Improving Stroke Prevention Among Hospitalized Oral-Anticoagulation-Naïve Patients With Atrial Fibrillation: A Randomized Trial.
    Silbernagel G; Spirk D; Hager A; Baumgartner I; Kucher N
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27451467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation.
    Noseworthy PA; Yao X; Deshmukh AJ; Van Houten H; Sangaralingham LR; Siontis KC; Piccini JP; Asirvatham SJ; Friedman PA; Packer DL; Gersh BJ; Shah ND
    J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26541393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral anticoagulation for prevention of thromboembolism in non-rheumatic atrial fibrillation: indications, effectiveness and risk].
    Kottkamp H; Willems S; Hindricks G; Chen X; Haverkamp W; Hasfeld M; Borggrefe M; Breithardt G
    Z Kardiol; 1993 Nov; 82(11):667-73. PubMed ID: 8291287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings.
    Mikkelsen AP; Hansen ML; Olesen JB; Hvidtfeldt MW; Karasoy D; Husted S; Johnsen SP; Brandes A; Gislason G; Torp-Pedersen C; Lamberts M
    Europace; 2016 Apr; 18(4):492-500. PubMed ID: 26443443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
    Hohnloser SH; Pajitnev D; Pogue J; Healey JS; Pfeffer MA; Yusuf S; Connolly SJ;
    J Am Coll Cardiol; 2007 Nov; 50(22):2156-61. PubMed ID: 18036454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.